Lynparza was approved in the European Union as a monotherapy for the maintenance treatment of adult patients with germline BRCA1/2 mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
